Skip to main content

Pulmonary hypertension

Latest articles

06-03-2017 | Pulmonary hypertension | News | Article

Systemic sclerosis associated with poor survival in CTD-PAH

A Chinese cohort study identifies factors associated with prognosis among patients with connective tissue disease-associated pulmonary arterial hypertension.

03-03-2017 | Pulmonary hypertension | News | Article

Right atrial strain associated with clinical outcomes in PAH

Study results suggest that right atrial strain could predict adverse outcomes among patients with pulmonary arterial hypertension.

10-02-2017 | Pulmonary hypertension | News | Article

Post-treatment pulmonary arterial compliance best predicts PAH prognosis

Evaluation of pulmonary arterial compliance after initiation or escalation of therapy for pulmonary arterial hypertension more accurately predicts prognosis than conventional right heart hemodynamic parameters, Italian study findings indicate.

02-02-2017 | Pulmonary hypertension | News | Article

Ambrisentan–tadalafil combination beneficial in CTD-associated PAH

A post-hoc subgroup analysis of the AMBITION trial suggests that the benefits of ambrisentan and tadalafil combination therapy extend to patients with connective tissue disease-associated pulmonary arterial hypertension.

20-01-2017 | Pulmonary hypertension | News | Article

Biological similarities between Cpc-PH and PAH identified

Research published in the Journal of the American College of Cardiology suggests that there could be a pathophysiological overlap between combined post-capillary and pre-capillary pulmonary hypertension and pulmonary arterial hypertension.

17-01-2017 | Pulmonary hypertension | News | Article

NT-proBNP promising biomarker for SSc-PAH

N-terminal pro-B-type natriuretic peptide may be more accurate than B-type natriuretic peptide for detecting and monitoring pulmonary arterial hypertension in patients with systemic sclerosis, study findings suggest.

11-01-2017 | Pulmonary hypertension | News | Article

Pulmonary artery aneurysm associated with cardiac dysfunction in PAH

Study results suggest that pulmonary artery aneurysm is associated with cardiac dysfunction among patients with pulmonary arterial hypertension.

14-12-2016 | Pulmonary hypertension | News | Article

PAH hospitalizations becoming less common but more costly

Pulmonary arterial hypertension-related hospitalization rates have fallen significantly in the USA since 2001, but the cost of each hospitalization has risen substantially and is increasingly paid for by Medicare, study findings indicate.

13-12-2016 | Pulmonary hypertension | News | Article

Exercise modulates immune system in IPAH

A single bout of exercise causes immediate changes in circulating T lymphocyte levels and improvements in the altered cytokine profile of patients with idiopathic pulmonary arterial hypertension, without aggravating the inflammatory state, researchers report.

09-12-2016 | Pulmonary hypertension | News | Article

Right ventricular wall thickness predicts PH outcomes

Right ventricular relative wall thickness is associated with prognosis in patients with pulmonary hypertension, researchers report.

11-11-2016 | Pulmonary hypertension | News | Article

Increased DPG predicts mortality in pulmonary hypertension

The risk for death increases with increasing diastolic pulmonary gradient in patients with World Health Organization group 1 pulmonary hypertension, American research suggests.

10-11-2016 | Pulmonary hypertension | News | Article

Undiagnosed connective tissue disease common in iPAH

Around one-third of patients with idiopathic pulmonary arterial hypertension may have an undiagnosed connective tissue disease, according to Italian researchers.

09-11-2016 | Pulmonary hypertension | News | Article

NO metabolites predict IPAH outcomes

Reduced nitric oxide synthesis appears to play a role in the pathogenesis of idiopathic pulmonary arterial hypertension and measuring plasma levels of the resulting nitrate and nitrite metabolites could help predict outcome, research suggests.

08-11-2016 | Pulmonary hypertension | News | Article

Clinicoserologic factors predict PAH risk in SSc patients

An Australian research team has pinpointed several clinical and serologic parameters that identify systemic sclerosis patients at risk of developing pulmonary arterial hypertension.

07-11-2016 | Pulmonary hypertension | News | Article

AMBITION analysis hints at PAH survival benefit with upfront combination therapy

A post-hoc analysis of the AMBITION trial raises the possibility that upfront combination therapy could have a beneficial effect on the survival of patients with pulmonary arterial hypertension.

07-10-2016 | Pulmonary hypertension | News | Article

Gas exchange during exercise pinpoints PAH severity

Including gas exchange measurements during the 6-minute walk distance test may give a better indication of disease severity in patients with pulmonary arterial hypertension than the walk test alone, researchers report.

06-10-2016 | Pulmonary hypertension | News | Article

Multiple mutations signal poor PAH outcomes

Patients with multiple mutations in genes linked to pulmonary artery hypertension have severe disease and a poor response to treatment, report researchers.

05-10-2016 | Pulmonary hypertension | News | Article

Cardiac catheterisation underused in patients started on PAH therapy

Performing right heart catheterisation to classify pulmonary arterial hypertension ahead of initiating medication, in line with consensus guidelines, does not appear to be carried out as often as it should, findings from a US-based population suggest.

08-07-2016 | Pulmonary hypertension | News | Article

PAH patient-reported outcome instrument developed

Researchers have developed the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire, which they say captures symptoms and impacts relevant to the patient population.

07-07-2016 | Pulmonary hypertension | News | Article

Real-world ambrisentan safety profile as expected

Analysis of the VOLibris Tracking post-marketing registry shows no new safety issues for ambrisentan used in patients with pulmonary arterial hypertension.